Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 5/20 | 0.50 |
| ▸ | MTTP | P55157 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KLRK1 | P26718 | 2/20 | 0.44 |
| ▸ | MICA | Q29983 | 2/20 | 0.44 |
| ▸ | RAET1L | Q5VY80 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | APOB | P04114 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704730 | 0.91 | NPY2R (0.57) | NPY2RMTTPKDM4EGAAALDH1A1 | |
| SCHEMBL6706883 | 0.85 | NPY2R (0.53) | NPY2RMTTPKDM4EGAAALDH1A1 | |
| SCHEMBL6706076 | 0.81 | NPY2R (0.49) | NPY2RMTTPKDM4EGAAALDH1A1 | |
| SCHEMBL6706746 | 0.80 | NPY2R (0.56) | NPY2RMTTPKDM4EGAAALDH1A1 | |
| SCHEMBL5742603 | 0.80 | NPY2R (0.68) | NPY2RMTTPKDM4EGAAALDH1A1 | |
| SCHEMBL6708421 | 0.80 | NPY2R (0.62) | NPY2RMTTPKDM4EGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL2588198 | 0.79 | NPY2R (0.67) | NPY2RMTTPKDM4EGAAALDH1A1 | |
| SCHEMBL12174540 | 0.79 | NPY2R (0.66) | NPY2RMTTPKDM4EGAAALDH1A1 | |
| SCHEMBL6706796 | 0.78 | NPY2R (0.65) | NPY2RMTTPKDM4EGAAALDH1A1 | |
| SCHEMBL6704491 | 0.78 | MTTP (0.48) | NPY2RMTTPALDH1A1MAPTKLRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-02-05 | — | — | US | claimed |
| EP-1289971-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | claimed |
| WO-2001092241-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-06 | — | — | WO | claimed |
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1289971-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092241-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | APOB, APOL1, CETP | NPY2R 983/4885MTTP 6/4885KDM4E 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.